
IPO: Marinomed sets offer price
According to the Austrian formulation specialist, 299,000 new bearer shares were placed with investors consisting of 260,000 shares from the base...

XyloCor Therapeutics bags US$17m in Series A financing
The Amsterdam-based company said it will primarily use the proceeds to advance its lead product XC001, licenced from Weill Cornell Medicine, to...

Amal bags €21.2m financing
All existing investors – Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund, VI Partners, High-Tech Gründerfonds, and...

AZ checkpoint blocker combo fails in head and neck cancer
It's another setback for combinations of checkpoint inhibitors as treatments of cancer; following a recent failure of a combo of AstraZeneca's PD-L1...

Jennewein Biotechnologie expands into Chinese market
According to a Memorandum of Understanding, the companies will combine Yili's know-how in Chinese breast milk composition and Jennewein...

Roche targets asthma with inhalable JAK1 blocker
The team headed by Nico Ghilardi targeted of Janus Kinase 1 (JAK1) with an inhalable small molecule inhibitor for two reasons:...


BioFIT: innovation and investors
Around 1.500 people came to Lille to participate in the event. BioFIT is hitting a nerve, says Etienne Varvaecke. The general manager of Eurosanté,...